文献速递产科

普萘洛尔对妊娠人类子宫肌层缩宫素诱导收缩力的影响:一项离体实验室研究

Propranolol and Oxytocin-Induced Contractility in Gravid Human Myometrium: An Ex Vivo Laboratory Study.
PubMed 文献 · BJOG · 2025-03-24

该前瞻性离体实验室研究在器官浴槽中采用择期剖宫产获得的足月子宫肌层样本,建立低剂量缩宫素引产-加强模型和高剂量缩宫素产后出血模型,发现普萘洛尔预处理可提高低剂量缩宫素诱导的子宫肌层收缩力曲线下面积(相对差异20.4%,95%CI 1.4%-43.2%,P=0.035),在缩宫素脱敏产后出血模型中预处理、同期处理及两者联合均提高高剂量缩宫素诱导的收缩力。作者认为离体研究提示引产加强早期给予普萘洛尔可使子宫活动增强约20%-25%,需临床研究确定其体内相关性。

要点

  • 低剂量缩宫素引产-加强模型中,普萘洛尔预处理组子宫肌层收缩力曲线下面积较对照组高20.4%(95%CI 1.4%-43.2%,P=0.035)。
  • 缩宫素脱敏产后出血模型中,普萘洛尔预处理、同期处理及预处理联合同期处理均提高高剂量缩宫素诱导的收缩力。
  • 作者认为离体研究提示引产加强早期给予普萘洛尔可使子宫活动增强约20%-25%,需临床研究确定其体内相关性。

核心结论

  • 离体研究提示,在引产和加强早期给予普萘洛尔可使子宫活动增强约20%-25%。
  • 需开展临床研究以确定这些发现与体内情况的相关性。

研究设计与样本

  • 前瞻性离体实验室研究,在器官浴槽中采用择期剖宫产获得的足月子宫肌层样本。
  • 建立两个模型:低剂量缩宫素引产-加强模型(3组分别于模拟分娩前及分娩中给予普萘洛尔,另设对照组)和高剂量缩宫素产后出血模型(4组分别于加强分娩期间和/或之后给予普萘洛尔,另设对照组)。
  • 采用力传感器记录子宫肌层收缩力,主要结局为收缩力曲线下面积。

主要发现

  • 引产-加强模型中,普萘洛尔预处理组低剂量缩宫素诱导的子宫肌层收缩力曲线下面积较对照组高(相对百分比差异20.4%,95%CI 1.4%-43.2%,P=0.035)。
  • 引产-加强模型中,分娩启动后给予普萘洛尔与对照组相比未观察到差异。
  • 缩宫素脱敏产后出血模型中,高剂量缩宫素诱导的子宫肌层收缩力曲线下面积在普萘洛尔预处理组较对照组高(差异25.4%,95%CI 0.2%-56.8%,P=0.048)。
  • 缩宫素脱敏产后出血模型中,同期处理组较对照组高(差异26.7%,95%CI 3.7%-54.7%,P=0.02)。
  • 缩宫素脱敏产后出血模型中,预处理联合同期处理组较对照组高(差异28.4%,95%CI 7.0%-54.1%,P=0.007)。

临床怎么用

  • 作者认为离体研究提示引产加强早期给予普萘洛尔可使子宫活动增强约20%-25%,需临床研究确定其体内相关性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the effect of propranolol on myometrial contractions induced by low dose and high dose oxytocin. DESIGN: Prospective ex vivo laboratory study. SETTING: Mount Sinai Hospital, Toronto. POPULATION: Full-term parturients who underwent elective caesarean deliveries (CD). METHODS: Two models were developed in the organ bath chamber using myometrial samples obtained during CDs: (i) Labor induction-augmentation model with low-dose oxytocin consisting of 3 groups with the administration of propranolol before and during simulated labor, and a control group. (ii) Postpartum haemorrhage (PPH) model with high-dose oxytocin consisting of 4 groups with the administration of propranolol during and/or after augmented labor (desensitised with oxytocin), and a control group. MAIN OUTCOME MEASURES: Myometrial contractility was recorded using force transducers. RESULTS: In the labor induction-augmentation model, propranolol pre-treatment produced a higher area under the curve (AUC) of myometrial contractility induced by low-dose oxytocin (relative percentage difference [diff]: 20.4%; 95% CI [1.4%, 43.2%], p = 0.035) compared to control; however, no difference was observed when propranolol was given after the initiation of labor. In the oxytocin-desensitised PPH model, the AUC of myometrial contractility induced by high-dose oxytocin was improved with propranolol pre-treatment (diff 25.4% [0.2%, 56.8%], p = 0.048), co-treatment (diff 26.7% [3.7%, 54.7%], p = 0.02), and both pre- and co-treatment (diff 28.4% [7.0%, 54.1%], p = 0.007) when compared to the control group. CONCLUSIONS: Our ex vivo study suggests that propranolol can augment uterine activity by approximately 20%-25% when administered early during labor induction and augmentation. Clinical studies are warranted to determine the relevance of these findings in vivo. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03434444; https://clinicaltrials.gov/.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Balki M, Miller LM, Caliaperumal J, et al. Propranolol and Oxytocin-Induced Contractility in Gravid Human Myometrium: An Ex Vivo Laboratory Study. BJOG. 2025. PMID: 40129234. doi:10.1111/1471-0528.18146

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。